Drugs / PBPV
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05622942 | Mar → Sep 2023 | pneumonia | CanSino Biologics Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PBPV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05622942 ↗ |
| Modality | Vaccine | “recombinant pneumococcal protein vaccine” NCT05622942 ↗ |
| Route | Intramuscular | “Intramuscular injection, 1 dose of 0.5ml inoculated on day 0” NCT05622942 ↗ |